Humacyte is a commercial-stage regenerative medicine company with one FDA-approved product: Symvess, a bioengineered human blood vessel used as a vascular conduit to repair damaged arteries. Symvess is grown from human vascular cells on a biodegradable scaffold, then decellularized to remove immune-triggering components, making it an off-the-shelf vessel that any patient can receive without rejection risk. Over time, the patient's own cells repopulate the vessel, potentially enabling self-repair — an advantage Humacyte argues over both synthetic grafts (infection-prone, non-healing) and autologous vein (time-consuming to harvest and not always available). Humacyte launched Symvess commercially in early 2025, selling directly to hospitals through a small field sales team targeting roughly 200 Level I Trauma Centers in the U.S. Revenue is per-unit product sales at a list price of approximately $24,250. The primary commercial bottleneck is hospital procurement: each hospital requires a VAC approval process taking 6–9 months, though Symvess also has listing with the U.S. Defense Logistics Agency, enabling purchases at military and VA hospitals without a separate VAC process. Humacyte manufactures Symvess at its Durham, NC facility and shares U.S. revenue with Fresenius Medical Care, which also holds exclusive rights to commercialize the product outside the U.S. and EU. Beyond trauma, Humacyte's pipeline targets hemodialysis AV access (its largest near-term opportunity), peripheral artery disease, and coronary artery bypass grafting, each using the same manufacturing platform.